However, triple negative-breast cancer (TNBC), which is characterized by the lack of an estrogen receptor (ER), progesterone receptor (PR), and Her-2 overexpression, could not benefit from both endocrine therapy and Her-2 targeted therapy [3]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.